-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, affects more than 3.
1 million people
in the United States.
Acute severe ulcerative colitis (ASUC) is a medical emergency characterized by more than 6 stools per day plus tachycardia > 90 beats per minute (bpm), fever > 37.
8°C, haemoglobin < 10.
5 gm/dL, and/or erythrocyte sedimentation rate (ESR) > 30 mm/hour
, according to Truelove and Witts criteria.
Severe episodes of IBD often require hospitalization, which has a significant financial cost
.
Length of stay (LOS) is often used to measure the efficiency of healthcare facilities, with the average length of stay in the United States being 4.
5 days
.
Patients with IBD have a longer length of hospital stay (mean LOS 5.
6 days).
The objective of this study was to identify factors
that predict prolonged hospitalized LOS in patients with ASUC.
The researchers performed data analysis
on all adult ASUC-related hospitalizations at UCSF between July 1, 2014 and December 31, 2017.
Univariate and multivariate analyses were then performed to determine factor days associated with LOS < 7 days and ≥ 7 days
.
Subgroup analyses were performed while excluding patients
who underwent colectomy during hospitalization.
The results of the study showed that a total of 95 patients associated with ASUC were hospitalized in this study
.
Initial univariate analysis identified the following factors associated with LOS ≥ 7 days (P < 0.
05): higher maximum heart rate in the first 24 hours, higher C-reactive protein, no biotherapy, and late hospital days for initiation of biotherapy.
In mixed-model multivariate analyses, hospitalization days with late initiation of biologics were associated with an increased LOS ≥ of 7 days (OR 3.
1, 95% CI 1.
2–7.
56, p=0.
012).
This study confirms multiple predictors of longer hospital stay, including factors
related to disease severity (non-modifiable) and treatment (possibly modifiable).
Importantly, this study identified biotin treatment status and delayed initiation of biotin therapy in hospitalized patients who ultimately did not require colectomy as predictors
of longer LOS (≥ 7 days).
Original source:
Alyssa Caplan.
et al.
Delayed Initiation of Rescue Therapy Associated with Increased Length of Stay in Acute Severe Ulcerative Colitis.
Digestive Diseases and Sciences.
2022.